Tetra Bio-Pharma (TBPMF) Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and Cannabinoid-Based Topical Cream

Tetra Bio-Pharma Discusses FDA Orphan Drug Designation for Its Ophthalmic P

 Tetra Bio-Pharma Inc. (TBPMF) Expands on its Orphan Drug Development Program and Management Update

Tetra Expands on its Orphan Drug Development Program and Management Update

Tetra Bio-Pharma Inc. (TBPMF) Offers Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions

Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Compani

Tetra Bio Pharma Inc. (TBPMF) Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011

Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC fo

Tetra Bio-Pharma Inc. (TBPMF) Announces Closing of Bought Deal Financing

Tetra Bio-Pharma Announces Closing of Bought Deal Financing Tetra Bio-Pharm

 Tetra Bio-Pharma Inc. (TBPMF) Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003

Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical S

Tetra Bio-Pharma Inc. (TBPMF) Announces Upsizing of Previously Announced Offering

Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering Tetra

Tetra Bio-Pharma Inc. (TBPMF) PRESS RELEASE CORRECTION

TETRA BIO-PHARMA – PRESS RELEASE CORRECTION Tetra Bio-Pharma Inc.(TSX

Tetra Bio-Pharma Inc. (TBPMF) Announces $10.0 Million Bought Deal Offering

Tetra Bio-Pharma Announces $10.0 Million Bought Deal Offering Tetra Bio-Pha

Tetra Bio-Pharma Inc. (TBPMF) Provides Update on its Commercialization Plan

Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC